Z-R-K-AOMK 新品

价格	询价
包装	1mg	10mg	100mg

最小起订量	1mg
发货地	江西
更新日期	2025-04-26

QQ交谈微信洽谈

产品详情

中文名称:Z-R-K-AOMK	英文名称:Z-R-K-AOMK
CAS:2810056-57-4	品牌: TanzhenBio
产地: 江西赣州	保存条件: -20℃
纯度规格: 98%	产品类别: CMK修饰肽
别名: Z-R-K-AOMK	主要用途: The peptide derivative Z-Arg-Lys-AOMK (1) was developed in our laboratories as a neutral pH-selective inhibitor of cathepsin B (Cat.B).5 Cat.B is believed to be released upon cellular injury from acidic lysosomes into the neutral pH cytoplasm and initiate and mediate inappropriate proteolytic degradation. Such sequelae are thought to be relevant to the pathogenesis observed with traumatic brain injury and neuropathies such as Alzheimer’s Disease. Our ongoing in vivo evaluations of Z-Arg-Lys-AOMK for its potential neurotherapeutic potential necessitated the scaled-up synthesis of this inhibitor.5 Upon embarking on this endeavor, we encountered several problems with the methodology employed in the previously published synthesis (Figure 1), which utilized solid-phase peptide synthesis and produced insufficient amounts of Z-Arg-Lys-AOMK
靶点: The peptide derivative Z-Arg-Lys-AOMK (1) was developed in our laboratories as a neutral pH-selective inhibitor of cathepsin B (Cat.B).5 Cat.B is believed to be released upon cellular injury from acidic lysosomes into the neutral pH cytoplasm and initiate and mediate inappropriate proteolytic degradation. Such sequelae are thought to be relevant to the pathogenesis observed with traumatic brain injury and neuropathies such as Alzheimer’s Disease. Our ongoing in vivo evaluations of Z-Arg-Lys-AOMK for its potential neurotherapeutic potential necessitated the scaled-up synthesis of this inhibitor.5 Upon embarking on this endeavor, we encountered several problems with the methodology employed in the previously published synthesis (Figure 1), which utilized solid-phase peptide synthesis and produced insufficient amounts of Z-Arg-Lys-AOMK	生物作用: The peptide derivative Z-Arg-Lys-AOMK (1) was developed in our laboratories as a neutral pH-selective inhibitor of cathepsin B (Cat.B).5 Cat.B is believed to be released upon cellular injury from acidic lysosomes into the neutral pH cytoplasm and initiate and mediate inappropriate proteolytic degradation. Such sequelae are thought to be relevant to the pathogenesis observed with traumatic brain injury and neuropathies such as Alzheimer’s Disease. Our ongoing in vivo evaluations of Z-Arg-Lys-AOMK for its potential neurotherapeutic potential necessitated the scaled-up synthesis of this inhibitor.5 Upon embarking on this endeavor, we encountered several problems with the methodology employed in the previously published synthesis (Figure 1), which utilized solid-phase peptide synthesis and produced insufficient amounts of Z-Arg-Lys-AOMK
应用: The peptide derivative Z-Arg-Lys-AOMK (1) was developed in our laboratories as a neutral pH-selective inhibitor of cathepsin B (Cat.B).5 Cat.B is believed to be released upon cellular injury from acidic lysosomes into the neutral pH cytoplasm and initiate and mediate inappropriate proteolytic degradation. Such sequelae are thought to be relevant to the pathogenesis observed with traumatic brain injury and neuropathies such as Alzheimer’s Disease. Our ongoing in vivo evaluations of Z-Arg-Lys-AOMK for its potential neurotherapeutic potential necessitated the scaled-up synthesis of this inhibitor.5 Upon embarking on this endeavor, we encountered several problems with the methodology employed in the previously published synthesis (Figure 1), which utilized solid-phase peptide synthesis and produced insufficient amounts of Z-Arg-Lys-AOMK

The peptide derivative Z-Arg-Lys-AOMK (1) was developed in our laboratories as a neutral pH-selective inhibitor of cathepsin B (Cat.B).5 Cat.B is believed to be released upon cellular injury from acidic lysosomes into the neutral pH cytoplasm and initiate and mediate inappropriate proteolytic degradation. Such sequelae are thought to be relevant to the pathogenesis observed with traumatic brain injury and neuropathies such as Alzheimer’s Disease. Our ongoing in vivo evaluations of Z-Arg-Lys-AOMK for its potential neurotherapeutic potential necessitated the scaled-up synthesis of this inhibitor.5 Upon embarking on this endeavor, we encountered several problems with the methodology employed in the previously published synthesis (Figure 1), which utilized solid-phase peptide synthesis and produced insufficient amounts of Z-Arg-Lys-AOMK

关键字： 2810056-57-4;

公司简介

南昌探真生物技术有限公司主要业务：多肽服务，肽核酸合成

成立日期	2019-02-05 （7年）	注册资本	300万人民币
员工人数	10-50人	年营业额	￥ 100万-300万
主营行业	生物活性小分子,有机合成试剂,氨基糖苷类	经营模式	贸易,工厂,试剂,定制,服务

南昌探真生物技术有限公司

VIP 5年

公司成立：7年
注册资本：300万人民币
企业类型：生产型
主营产品：多肽，放射显影化合物
公司地址：江西省南昌市小蓝经济技术开发区汇仁大道266号18栋1楼

进入店铺

询盘

店内推荐

cyclo(YRGDLAYp(NMe)K)

询价

PSMA-C8-K

询价

c(YRGDLAYp(NMe)K)

询价

Z-R-K-AOMK相关厂家报价

产品名称	价格		公司名称	报价日期
90105-02-55(Z),8(Z),14(Z)-Eicosatrienoic Acid	询价	VIP3年	上海嘉定区澄浏公路52号	2025-04-29
CATO_瑞舒伐他汀EP杂质K钙盐（Z-异构体）__97%	询价	VIP1年	广州佳途科技股份有限公司	2025-04-14
Z-Orn(Z)-OSu 90970-61-9	询价	VIP2年	宝鸡缔都医药化工有限公司	2025-04-22

内容声明:
以上所展示的信息由商家自行提供，内容的真实性、准确性和合法性由发布商家负责。商家发布价格指该商品的参考价格，并非原价，该价格可能随着市场变化，或是由于您购买数量不同或所选规格不同而发生变化。最终成交价格，请咨询商家，以实际成交价格为准。请意识到互联网交易中的风险是客观存在的